Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study on the Tolerability, Safety and Pharmacokinetics of Single-dose Dose Escalation and Multiple-dose Oral ZL-82 Tablets in Healthy Adult Subjects

NCT06055023 is registered in ClinicalTrials.gov with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT06055023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06055023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study on the Tolerability, Safety and Pharmacokinetics of Single-dose Dose Escalation and Multiple-dose Oral ZL-82 Tablets in Healthy Adult Subjects
Lead sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
April 9, 2023
Completion date
June 13, 2024
Enrollment
69 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory bowel disease - ibd1, rheumatoid arthritis (ra)